Age | Invasive carcinoma of breast | Disease TNM Breast tumor staging
Item
patients must be age 18 or older. histological or cytologically confirmed invasive breast cancer, with stage iv disease.
boolean
C0001779 (UMLS CUI [1])
C0853879 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C0474926 (UMLS CUI [3,2])
CNS metastases Measurable Radiography | CNS metastases Size T1 MRI gadolinium-enhanced | Absence Disease Except CNS
Item
evidence of radiographically measurable cns metastases (greater than or equal to 10mm on t1-weighted gadolinium-enhanced mri) within 2 weeks prior to starting treatment. patients without known extra-cns disease are eligible.
boolean
C0686377 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C0686377 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C2697938 (UMLS CUI [2,3])
C0855566 (UMLS CUI [2,4])
C0332197 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C0332300 (UMLS CUI [3,3])
C3714787 (UMLS CUI [3,4])
Metastatic malignant neoplasm to brain | Meningeal Carcinomatosis | Therapeutic radiology procedure Spine Involvement meningeal
Item
must have metastases in the brain. patients with concurrent leptomeningeal carcinomatosis are eligible for the study. local radiation to sites of meningeal involvement in the spine is allowed.
boolean
C0220650 (UMLS CUI [1])
C0220654 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0037949 (UMLS CUI [3,2])
C1314939 (UMLS CUI [3,3])
C0521400 (UMLS CUI [3,4])
Whole brain radiation therapy Previous Absent | Radiotherapy to brain Stereotactic | Lesion of brain New Measurable | Whole brain radiation therapy Expected
Item
no prior whole brain radiation. patients who had previous stereotactic brain irradiation are eligible, provided they have new measurable brain lesions (which has not been radiated previously) and will receive wbrt at 30gy over 10 fractions.
boolean
C1520143 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0948319 (UMLS CUI [2,1])
C0729296 (UMLS CUI [2,2])
C0221505 (UMLS CUI [3,1])
C0205314 (UMLS CUI [3,2])
C1513040 (UMLS CUI [3,3])
C1520143 (UMLS CUI [4,1])
C1517001 (UMLS CUI [4,2])
Excision CNS metastases | Measurable Disease Remaining Brain | Status post Operative Surgical Procedures
Item
may undergo surgical resection of cns metastases if clinically indicated, but must have remaining measurable disease in the brain after surgery.
boolean
C0728940 (UMLS CUI [1,1])
C0686377 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C1527428 (UMLS CUI [2,2])
C0006104 (UMLS CUI [2,3])
C0231290 (UMLS CUI [3,1])
C0543467 (UMLS CUI [3,2])
Capecitabine Adjuvant therapy Absent | Capecitabine Absent Neoplasm Metastasis | Fluorouracil Adjuvant therapy Completed | Fluorouracil Neoplasm Metastasis Treatment completed
Item
no prior treatment with capecitabine in the adjuvant or metastatic settings. patients may have completed 5-fluorouracil based treatment in the adjuvant setting or metastatic setting more than one year prior.
boolean
C0671970 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0671970 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,3])
C0016360 (UMLS CUI [3,1])
C0677850 (UMLS CUI [3,2])
C0205197 (UMLS CUI [3,3])
C0016360 (UMLS CUI [4,1])
C0027627 (UMLS CUI [4,2])
C0580352 (UMLS CUI [4,3])
trastuzumab | Treatment To be stopped
Item
patients who had previous trastuzumab therapy will be eligible but treatment will be discontinued prior to enrollment.
boolean
C0728747 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Cardiac ejection fraction Normal Range Echocardiography | Cardiac ejection fraction Normal Range MUGA scan
Item
cardiac ejection fraction within institutional range of normal as measure by echocardiogram or muga scans at baseline.
boolean
C0232174 (UMLS CUI [1,1])
C0086715 (UMLS CUI [1,2])
C0013516 (UMLS CUI [1,3])
C0232174 (UMLS CUI [2,1])
C0086715 (UMLS CUI [2,2])
C0521317 (UMLS CUI [2,3])
Hematologic function | Liver function | Renal function | Toxicity Due to Prior Chemotherapy | Patient recovered | Diphosphonates | ECOG performance status
Item
hematological adequacy hepatic adequacy renal adequacy must have recovered from toxicity of prior chemotherapy with laboratory values as specified above. concurrent treatment with bisphosphonates is permitted. performance status of ecog 0-1.
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0600688 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C1514457 (UMLS CUI [4,3])
C1115804 (UMLS CUI [5])
C0012544 (UMLS CUI [6])
C1520224 (UMLS CUI [7])
Life Expectancy | Major surgery | Able to swallow Oral medication | Ability Retain Oral medication
Item
life expectancy of at least 12 weeks. at least 3 weeks since major surgical procedures. able to swallow and retain oral medication.
boolean
C0023671 (UMLS CUI [1])
C0679637 (UMLS CUI [2])
C2712086 (UMLS CUI [3,1])
C0175795 (UMLS CUI [3,2])
C0085732 (UMLS CUI [4,1])
C0333118 (UMLS CUI [4,2])
C0175795 (UMLS CUI [4,3])
Pregnancy | Breast Feeding | Hypersensitivity Capecitabine | Fluorouracil allergy | Dihydropyrimidine Dehydrogenase Deficiency
Item
pregnant or breast feeding. known allergy to capecitabine or 5-fluorouracil. known to have dihydropyrimidine dehydrogenase (dpd) deficiency.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0671970 (UMLS CUI [3,2])
C0570698 (UMLS CUI [4])
C1959620 (UMLS CUI [5])
Meningeal Carcinomatosis | Site CNS metastases
Item
patients who have leptomeningeal carcinomatosis as the only site of cns metastases.
boolean
C0220654 (UMLS CUI [1])
C1515974 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
CYP3A4 Inhibitors | CYP3A4 Inducers
Item
patients taking concomitant medications which are cyp3a4 inhibitors or inducers.
boolean
C3850053 (UMLS CUI [1])
C3850041 (UMLS CUI [2])
Intrathecal chemotherapy Leptomeningeal Neoplasms | Mental disorders Adverse effects Compliance Oral medication | Addictive Behavior Adverse effects Compliance Oral medication
Item
patients who will receive intrathecal chemotherapy for leptomeningeal disease. patients with psychiatric or addictive disorders that would adversely effect compliance with oral medication.
boolean
C1517560 (UMLS CUI [1,1])
C0751297 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2,1])
C0879626 (UMLS CUI [2,2])
C1321605 (UMLS CUI [2,3])
C0175795 (UMLS CUI [2,4])
C0085281 (UMLS CUI [3,1])
C0879626 (UMLS CUI [3,2])
C1321605 (UMLS CUI [3,3])
C0175795 (UMLS CUI [3,4])
Life Expectancy | Lymphangitic spread Symptomatic Lung | Malabsorption Syndrome | Disease Affecting Gastrointestinal function | Gastrectomy | Small intestine excision
Item
life expectancy less than 3 months. symptomatic lymphangitic spread to lung. malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
boolean
C0023671 (UMLS CUI [1])
C3697833 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0024109 (UMLS CUI [2,3])
C0024523 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C0516983 (UMLS CUI [4,3])
C0017118 (UMLS CUI [5])
C0192601 (UMLS CUI [6])
Immediate hypersensitivity Gadolinium-based Contrast Agent | Delayed Hypersensitivity Gadolinium-based Contrast Agent
Item
history of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or other contraindication or gadolinium contrast.
boolean
C0020523 (UMLS CUI [1,1])
C3249258 (UMLS CUI [1,2])
C0020522 (UMLS CUI [2,1])
C3249258 (UMLS CUI [2,2])
Medical contraindication MRI | Artificial cardiac pacemaker | Implantation of internal cardiac defibrillator | Brain Aneurysm clip | Cochlear Implants | Ocular Foreign Body | Shrapnel
Item
other known contraindication to mri, such as a cardiac pacemaker, implanted cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel,
boolean
C1301624 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
C0030163 (UMLS CUI [2])
C1273352 (UMLS CUI [3])
C0006104 (UMLS CUI [4,1])
C0179977 (UMLS CUI [4,2])
C0009199 (UMLS CUI [5])
C3898107 (UMLS CUI [6])
C0522670 (UMLS CUI [7])
Vascular Disease | Communicable Disease Uncontrolled | Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Disease Free Duration
Item
1vascular disease within 12 months prior to enrollment uncontrolled infection history of other malignancy, except for curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. subjects with other malignancies who have been disease-free for at least 5 years are eligible
boolean
C0042373 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C1707251 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0007117 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C1273390 (UMLS CUI [5,2])
C0553723 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C1273390 (UMLS CUI [6,2])
C0851140 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0012634 (UMLS CUI [7,2])
C0332296 (UMLS CUI [7,3])
C0449238 (UMLS CUI [7,4])